Open access · CC-BY
via OpenAlex
Melatonin: Clinical Perspectives in Neurodegeneration
Frontiers in Endocrinology · 2019 · ▲ 198 citations
Abstract
Neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD) are important health problems and there is a growing recognition that both governmental and non-governmental organizations must make efforts to prevent, in addition to treat, them. In this context, the pineal product melatonin has a promising significance. Melatonin, an unusual phylogenetically conserved molecule present in all known aerobic organisms, is effective both as a chronobiotic and as a cytoprotective. As a chronobiotic, the afternoon increase in melatonin "opens the doors of sleep" every night and the therapeutic use of melatonin has been demonstrated to preserve slow wave sleep effectively. As a cytoprotective molecule, melatonin reverses the low degree inflammatory damage seen in neurodegenerative disorders and ageing. One of the characteristics of advancing age is the gradual decrease in the circulating levels of melatonin. Both in vitro and in vivo, melatonin prevented the neurodegeneration observed in experimental models of AD and PD. Melatonin also increased removal of toxic proteins by the brain glymphatic system. A limited number of clinical trials have indicated that melatonin has a potential therapeutic value as a neuroprotective drug in the treatment of AD, particularly at an early stage of cognitive impairment, and of PD. From animal studies the cytoprotective effects of melatonin need high doses to become apparent (i.e. in the 40-100 mg/day range). The off-label use of melatonin is discussed.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.3389/fendo.2019.00480
- Canonical
- link ↗
- Fetched
- 2026-10-17 MST
Cite this
APA
Cardinali, D.P. (2019). Melatonin: Clinical Perspectives in Neurodegeneration. <em>Frontiers in Endocrinology</em>. https://doi.org/10.3389/fendo.2019.00480
Vancouver
Cardinali DP. Melatonin: Clinical Perspectives in Neurodegeneration. Frontiers in Endocrinology. 2019. doi:10.3389/fendo.2019.00480.
BibTeX
@article{daniel2019Melato,
title = {Melatonin: Clinical Perspectives in Neurodegeneration},
author = {Daniel Pedro Cardinali},
journal = {Frontiers in Endocrinology},
year = {2019},
doi = {10.3389/fendo.2019.00480},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Family Medicine and Primary Care 2024
Open access · CC-BY
Arterial stiffness as a screening tool for cardiovascular risk in health and disease
Aging Cell 2022
Open access · CC-BY
Contribution of proteases to the hallmarks of aging and to age‐related neurodegeneration
Hypertension 2023
Open access · OA
Lifelong Heterogeneous Contribution of Cardiovascular Risk Factors to Slow and Fast Progression of Arterial Stiffness
Oxidative Medicine and Cellular Longevity 2016
Open access · CC-BY
Cross Talk of Proteostasis and Mitostasis in Cellular Homeodynamics, Ageing, and Disease
University Hospital, Bordeaux 2019
Open access · US-GOV
"Sleep, Rhythms and Risk of Alzheimer's Disease: a Daily Life Actigraphic Assessment and MRI Study" "SoRyMA - AMImage3"
Frontiers in Aging Neuroscience 2023
Open access · CC-BY